Simulations Plus, Inc. (SLP)
- Previous Close
50.04 - Open
49.96 - Bid 49.30 x 100
- Ask 49.57 x 100
- Day's Range
49.26 - 50.08 - 52 Week Range
32.69 - 52.69 - Volume
37,303 - Avg. Volume
104,808 - Market Cap (intraday)
1B - Beta (5Y Monthly) 0.68
- PE Ratio (TTM)
96.88 - EPS (TTM)
0.51 - Earnings Date Jul 4, 2024 - Jul 8, 2024
- Forward Dividend & Yield 0.24 (0.48%)
- Ex-Dividend Date Apr 26, 2024
- 1y Target Est
53.67
Simulations Plus, Inc. develops drug discovery and development software for modeling and simulation, and prediction of molecular properties utilizing artificial intelligence and machine learning based technology worldwide. The company operates through two segments, Software and Services. It offers GastroPlus, which simulates the absorption and drug interaction of compounds administered to humans and animals; and DDDPlus and MembranePlus simulation products. The company also provides products based on mechanistic and mathematical models, such as DILIsym, NAFLDsym, ILDsym, RENAsym, IPFsym, and MITOsym products. In addition, it offers Absorption, Distribution, Metabolism, Excretion, and Toxicity Predictor for chemistry-based computer program that takes molecular structures as inputs and predicts their properties; and MedChem Designer, as well as MonolixSuite products for modeling and simulation that allows for population analyses, rapid clinical trial data analyses, and regulatory submissions. Further, the company provides clinical-pharmacology-based consulting services, which includes population pharmacokinetic and pharmacodynamic modeling, exposure-response analyses, clinical trial simulations, data programming, and technical writing services in support of regulatory submissions; and early drug discovery services. Additionally, it offers creative and insightful consulting services to support its quantitative systems pharmacology/quantitative systems toxicology modelling. The company serves pharmaceutical, biotechnology, agrochemical, cosmetics, and food industry companies, as well as academic and regulatory agencies. Simulations Plus, Inc. was incorporated in 1996 and is headquartered in Lancaster, California.
www.simulations-plus.com192
Full Time Employees
August 31
Fiscal Year Ends
Sector
Industry
Recent News: SLP
Performance Overview: SLP
Trailing total returns as of 5/21/2024, which may include dividends or other distributions. Benchmark is .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: SLP
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: SLP
Valuation Measures
Market Cap
1.00B
Enterprise Value
892.57M
Trailing P/E
96.23
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
15.69
Price/Book (mrq)
5.65
Enterprise Value/Revenue
13.80
Enterprise Value/EBITDA
54.55
Financial Highlights
Profitability and Income Statement
Profit Margin
16.26%
Return on Assets (ttm)
4.43%
Return on Equity (ttm)
6.16%
Revenue (ttm)
64.67M
Net Income Avi to Common (ttm)
10.52M
Diluted EPS (ttm)
0.51
Balance Sheet and Cash Flow
Total Cash (mrq)
108.5M
Total Debt/Equity (mrq)
0.58%
Levered Free Cash Flow (ttm)
18.37M
Research Analysis: SLP
Company Insights: SLP
SLP does not have Company Insights